Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win
Published
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.
Full ArticlePublished
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.
Full ArticleWhile most of the global population is under lockdown to prevent the spread of the coronavirus, many laboratories in the pharma..